In addition, in HT29 tumor cells that are resistant to PI-103 through rapid glucuronidation to an inactive metabolite [34], we showed that the metabolically stable, potent and selective pan-class I PI3 Kinase inhibitor and investigational clinical agent GDC-0941 [42,43] also increased sensitivity to TRAIL. Here, TNFSF10 is linked to neoplasm.